Drug Trial Radar · NCT05662332
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
795
Actual
Start
Jan 14, 2023
Primary completion
Jul 19, 2024
Study completion Jul 19, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who are starting basal insulin therapy for the first time.
Conditions
- Type 2 Diabetes
- T2D
Interventions
Insulin Efsitora AlfaDrug
Administered SC
Insulin GlargineDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis]Time frame: Baseline, Week 52
Locations
71 sites in 4 countries. Site status is shown where the registry gives one.
Cahaba Research
Birmingham, Alabama
Syed Research Consultants Llc
Sheffield, Alabama
AMCR Institute
Escondido, California
Velocity Clinical Research, Gardena
Gardena, California
National Research Institute - Huntington Park
Huntington Park, California
National Research Institute - Wilshire
Los Angeles, California
Diabetes Associates Medical Group
Orange, California
Encompass Clinical Research
Spring Valley, California
Millennium Clinical Trials
Thousand Oaks, California
University Clinical Investigators, Inc.
Tustin, California
Diablo Clinical Research, Inc.
Walnut Creek, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Chase Medical Research, LLC
Waterbury, Connecticut
Clinical Research of West Florida, Inc. (Clearwater)
Clearwater, Florida
Suncoast Research Group
Miami, Florida
Clinical Research of West Florida
Tampa, Florida
Center for Advanced Research & Education
Gainesville, Georgia
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
Springfield, Illinois
American Health Network of Indiana, LLC - Franklin
Franklin, Indiana
American Health Network of Indiana, LLC - Muncie
Muncie, Indiana
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
Clinvest Research LLC
Springfield, Missouri
University Of Nebraska Medical Center
Omaha, Nebraska
Mid Hudson Medical Research
New Windsor, New York
Meridian Clinical Research, LLC
Vestal, New York
Intend Research, LLC
Norman, Oklahoma
Decpa, Llc
Feasterville-Trevose, Pennsylvania
Office 18
Pittsburgh, Pennsylvania
WR-Clinsearch, LLC
Chattanooga, Tennessee
Private Practice - Dr. Osvaldo A. Brusco
Corpus Christi, Texas
Dallas Diabetes Research Center
Dallas, Texas
Prime Revival Research Institute
Flower Mound, Texas
Endocrine Associates
Houston, Texas
Endocrine Ips, Pllc
Houston, Texas
North Hills Family Medicine/North Hills Medical Research
North Richland Hills, Texas
Texas Valley Clinical Research
Weslaco, Texas
Eastside Research Associates
Redmond, Washington
Fundación Respirar
Buenos Aires, Argentina
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.